Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2019

25.10.2018 | Breast Oncology

Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ

verfasst von: Faina Nakhlis, MD, Beth T. Harrison, MD, Catherine S. Giess, MD, Susan C. Lester, MD, PhD, Kevin S. Hughes, MD, Suzanne B. Coopey, MD, Tari A. King, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

A diagnosis of non-classic lobular carcinoma in situ (NC-LCIS) encompasses a variety of lesions with poorly characterized natural history. We evaluated upgrade rates and factors associated with upgrade to malignancy following a core biopsy diagnosis of NC-LCIS, and its natural history.

Methods

Upon Institutional Review Board approval, pathology databases were searched for NC-LCIS core biopsy diagnoses (carcinoma in situ [CIS], CIS with ductal and lobular features [CIS/DLF], pleomorphic LCIS [P-LCIS], variant LCIS [V-LCIS], LCIS with necrosis). Cases with available core and excision pathology were included, while cases with concurrent ipsilateral invasive carcinoma (IC), ductal carcinoma in situ (DCIS), and/or atypical ductal hyperplasia were excluded.

Results

Overall, 121 NC-LCIS cases were identified from 1998 to 2017. We excluded 46 cases with concurrent cancer; 75 patients with 76 NC-LCIS core biopsy diagnoses followed by excision formed our study cohort. Median age was 56 years (range 41–83), and all imaging findings were classified as Breast Imaging Reporting and Data System 4; calcifications were the most common biopsy indication (80%). Excision yielded malignancy in 27 (36%) patients (IC 17, 63%; DCIS alone 10, 37%). We were unable to identify radiologic or pathologic features predictive of upgrade. Of 49 pure NC-LCIS cases, 15 (31%) had mastectomy, 9 (18%) had excision and radiation, and 25 (51%) had excision alone. At a median follow-up of 58 months (range 1–224), 1/25 (4%) patients with excision alone developed ipsilateral DCIS 14 months later.

Conclusions

In this series of NC-LCIS, 36% of cases were upgraded, supporting routine excision. We were unable to identify predictors of upgrade. Among 25 patients with pure NC-LCIS, only one patient developed a future ipsilateral cancer. Further study of the natural history of NC-LCIS is warranted.
Literatur
1.
Zurück zum Zitat Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver M. WHO Classification of Tumours of the Breast, 4th ed. Lyon: IARC Press; 2012. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver M. WHO Classification of Tumours of the Breast, 4th ed. Lyon: IARC Press; 2012.
2.
Zurück zum Zitat Fadare O, Dadmanesh F, Alvarado-Cabrero I, et al. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: a clinicopathologic study of 18 cases. Am J Surg Pathol 2006;30:1445–53.CrossRefPubMed Fadare O, Dadmanesh F, Alvarado-Cabrero I, et al. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: a clinicopathologic study of 18 cases. Am J Surg Pathol 2006;30:1445–53.CrossRefPubMed
3.
Zurück zum Zitat Alvarado-Cabrero I, Picon Coronel G, Valencia Cedillo R, Canedo N, Tavassoli FA. Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: a clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma. Arch Med Res 2010;41:436–41.CrossRefPubMed Alvarado-Cabrero I, Picon Coronel G, Valencia Cedillo R, Canedo N, Tavassoli FA. Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: a clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma. Arch Med Res 2010;41:436–41.CrossRefPubMed
4.
Zurück zum Zitat Tavassoli FA. Lobular neoplasia: evolution of its significance and morphologic spectrum. Int J Surg Pathol 2010;18(3 Suppl):174S–7S.CrossRefPubMed Tavassoli FA. Lobular neoplasia: evolution of its significance and morphologic spectrum. Int J Surg Pathol 2010;18(3 Suppl):174S–7S.CrossRefPubMed
5.
Zurück zum Zitat Shin SJ, Lal A, De Vries S, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol 2013;44:1998–2009.CrossRefPubMed Shin SJ, Lal A, De Vries S, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol 2013;44:1998–2009.CrossRefPubMed
6.
Zurück zum Zitat Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rev 1996;1:27–30.CrossRef Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rev 1996;1:27–30.CrossRef
7.
Zurück zum Zitat Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002;15:1044–50.CrossRefPubMed Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002;15:1044–50.CrossRefPubMed
8.
Zurück zum Zitat Gomes DS, Porto SS, Balabram D, Gobbi H. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Diagn Pathol 2014;9:121.CrossRefPubMedPubMedCentral Gomes DS, Porto SS, Balabram D, Gobbi H. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Diagn Pathol 2014;9:121.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med 2010;134:1024–8.PubMed Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med 2010;134:1024–8.PubMed
10.
Zurück zum Zitat Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol 2001;176:1255–9.CrossRefPubMed Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol 2001;176:1255–9.CrossRefPubMed
11.
Zurück zum Zitat Lavoue V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Leveque J. Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow-up surgical excision. Breast 2007;16:533–9.CrossRefPubMed Lavoue V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Leveque J. Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow-up surgical excision. Breast 2007;16:533–9.CrossRefPubMed
12.
Zurück zum Zitat Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol 2008;32:1721–6.CrossRefPubMed Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol 2008;32:1721–6.CrossRefPubMed
13.
Zurück zum Zitat Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC, Sharma N. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology 2010;57:472–8.CrossRefPubMed Carder PJ, Shaaban A, Alizadeh Y, Kumarasuwamy V, Liston JC, Sharma N. Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology 2010;57:472–8.CrossRefPubMed
14.
Zurück zum Zitat Niell B, Specht M, Gerade B, Rafferty E. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol 2012;199:929–35.CrossRefPubMed Niell B, Specht M, Gerade B, Rafferty E. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol 2012;199:929–35.CrossRefPubMed
15.
Zurück zum Zitat Meroni S, Bozzini AC, Pruneri G, et al. Underestimation rate of lobular intraepithelial neoplasia in vacuum-assisted breast biopsy. Eur Radiol 2014;24:1651–8.CrossRefPubMed Meroni S, Bozzini AC, Pruneri G, et al. Underestimation rate of lobular intraepithelial neoplasia in vacuum-assisted breast biopsy. Eur Radiol 2014;24:1651–8.CrossRefPubMed
16.
Zurück zum Zitat Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol 2015;22:4263–9.CrossRefPubMedPubMedCentral Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol 2015;22:4263–9.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Susnik B, Day D, Abeln E, et al. Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer 2016;16:507–13.CrossRefPubMed Susnik B, Day D, Abeln E, et al. Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer 2016;16:507–13.CrossRefPubMed
18.
Zurück zum Zitat Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: clinicopathologic features and correlation with subsequent excision. Clin Breast Cancer. 2018;18:e449–e454.CrossRefPubMed Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: clinicopathologic features and correlation with subsequent excision. Clin Breast Cancer. 2018;18:e449–e454.CrossRefPubMed
19.
Zurück zum Zitat Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 2011;135:737–43.PubMed Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med 2011;135:737–43.PubMed
20.
Zurück zum Zitat De Brot M, Koslow Mautner S, Muhsen S, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat 2017;165:411–20.CrossRefPubMedPubMedCentral De Brot M, Koslow Mautner S, Muhsen S, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat 2017;165:411–20.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology 2014;64:981–93.CrossRefPubMedPubMedCentral Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology 2014;64:981–93.CrossRefPubMedPubMedCentral
22.
Metadaten
Titel
Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ
verfasst von
Faina Nakhlis, MD
Beth T. Harrison, MD
Catherine S. Giess, MD
Susan C. Lester, MD, PhD
Kevin S. Hughes, MD
Suzanne B. Coopey, MD
Tari A. King, MD
Publikationsdatum
25.10.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6937-0

Weitere Artikel der Ausgabe 1/2019

Annals of Surgical Oncology 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.